To determine whether 2 days of staging at 2500–3500 m, combined with either high or low physical activity, reduces acute mountain sickness (AMS) during subsequent ascent to 4300 m.
Methods:
Three independent groups of unacclimatized men and women were staged for 2 days at either 2500 m (n = 18), 3000 m (n = 16), or 3500 m (n = 15) before ascending and living for 2 days at 4300 m and compared with a control group that directly ascended to 4300 m (n = 12). All individuals departed to the staging altitudes or 4300 m after spending one night at 2000 m during which they breathed supplemental oxygen to simulate sea level conditions. Half in each group participated in ∼3 hours of daily physical activity while half were sedentary. Women accounted for ∼25% of each group. AMS incidence was assessed using the Environmental Symptoms Questionnaire. AMS was classified as mild (≥0.7 and <1.5), moderate (≥1.5 and <2.6), and severe (≥2.6).
Results:
While staging, the incidence of AMS was lower (p < 0.001) in the 2500 m (0%), 3000 m (13%), and 3500 m (40%) staged groups than the direct ascent control group (83%). After ascent to 4300 m, the incidence of AMS was lower in the 3000 m (43%) and 3500 m (40%) groups than the 2500 m group (67%) and direct ascent control (83%). Neither activity level nor sex influenced the incidence of AMS during further ascent to 4300 m.
Conclusions:
Two days of staging at either 3000 or 3500 m, with or without physical activity, reduced AMS during subsequent ascent to 4300 m but staging at 3000 m may be recommended because of less incidence of AMS.
Get full access to this article
View all access options for this article.
References
1.
BancheroN, SimeF, PenalozaD, CruzJ, GamboaR, and MarticorenaE. (1966). Pulmonary pressure, cardiac output, and arterial oxygen saturation during exercise at high altitude and sea level. Circulation, 33:249–262.
2.
BärtschP, ShawS, FranciolliM, GnadingerMP, and WeidmannP. (1988). Atrial natriuretic peptide in acute mountain sickness. J Appl Physiol, 65:1929–1937.
3.
BasnyatB. (2014). Pro: Pulse oximetry is useful in predicting acute mountain sickness. High Alt Med Biol, 15:440–441.
4.
BeidlemanBA, FulcoCS, CadaretteBS, CymermanA, BullerMJ, SalgadoRM, PoschAM, StaabJE, YurkeviciusBR, LuippoldAJ, WellesAP, and MuzaSR. (2017a). Is normobaric hypoxia an effective treatment for sustaining previously acquired altitude acclimatization. J Appl Physiol, 123:1214–1227.
5.
BeidlemanBA, FulcoCS, MuzaSR, RockPB, StaabJE, ForteVA, BrotherMD, and CymermanA. (2009). Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 m. High Alt Med Biol, 10:253–260.
6.
BeidlemanBA, MuzaSR, FulcoCS, RockPB, and CymermanA. (2007). Validation of a shortened electronic version of the Environmental Symptoms Questionnaire. High Alt Med Biol, 8:192–199.
7.
BeidlemanBA, MuzaSR, RockPB, FulcoCS, LyonsTP, HoytRW, and CymermanA. (1997). Exercise responses after altitude acclimatization are retained during reintroduction to altitude. Med Sci Sports Exerc, 29:1588–1595.
8.
BeidlemanBA, RockPB, MuzaSR, FulcoCS, ForteVAJ, and CymermanA. (1999). Exercise Ve and physical performance are not affected by menstrual cycle phase at altitude. J Appl Physiol, 86:1519–1526.
9.
BeidlemanBA, TighiouartH, SchmidCH, FulcoCS, and MuzaSR. (2013). Predictive models of acute mountain sickness after rapid ascent to various altitudes. Med Sci Sports Exerc, 45:792–800.
10.
BeidlemanBA, WellesAP, and BullerMJ. (2017b). Predicting individual risk of altitude illness using real-time monitoring of accumulated hypoxic debt. J Sci Med Sport, 20:S94–S95.
11.
BircherHP, EichenbergerU, MaggioriniM, OelzO, and BärtschP. (1994). Relationship of mountain sickness to physical fitness and exercise intensity during ascent. J Wilderness Med, 5:302–311.
12.
BurtscherM, BachmannO, HatzlT, HotterB, LikarR, PhiladelphyM, and NachbauerW. (2001). Cardiopulmonary and metabolic responses in healthy elderly humans during a 1-week programme at high altitude. Eur J Appl Physiol, 84:379–386.
13.
EvansWO, RobinsonSM, HorstmanDH, JacksonRE, and WeiskopfRB. (1976). Amelioration of the symptoms of acute mountain sickness by staging and acetazolamide. Aviat Space Environ Med, 47:512–516.
14.
GallagherSA, and HackettPH. (2004). High-altitude illness. Emerg Med Clin North Am, 22:329–355.
15.
Gavrvican-LewisLA, SharpeK, and GoreCJ. (2016). Time for a new metric for hypoxic dose. J Appl Physiol, 121:352–355.
16.
HackettPH, RennieD, HofmeisterSE, GroverRF, GroverEB, and ReevesJT. (1982). Fluid retention and relative hypoventilation in acute mountain sickness. Respiration, 43:321–329.
17.
HackettPH, RennieD, and LevineHD. (1976). The incidence, importance, and prophylaxis of acute mountain sickness. Lancet, 2:1149–1154.
18.
HackettPH, and RoachRC. (2001a). High-altitude medicine. In: Wilderness Medicine. AuerbachPS, ed. Mosby, Philadelphia. pp. 2–43.
19.
HackettPH, and RoachRC. (2001b). High altitude illness. N Engl J Med, 345:107–114.
20.
HagerER, TreuthMS, GormelyC, EppsL, SnitkerS, and BlackMM. (2015). Ankle accelerometry for assessing physical activity among adolescent girls: Threshold determination, validity, reliability, and feasibility. Res Q Exerc Sport, 86:397–405.
21.
HansenJE, HarrisCW, and EvansWO. (1967). Influence of elevation of origin, rate of ascent and a physical conditioning program on symptoms of acute mountain sickness. Mil Med, 132:585–592.
22.
HeilDP. (2006). Predicting activity energy expenditure using the Actical activity monitor. Res Q Exerc Sport, 77:64–80.
23.
HoytRW, and HonigA. (1996). Body fluid and energy metabolism at high altitude. In: Handbook of Physiology: Section 4: Environmental Physiology. FregleyMJ and BlatteisCM, eds. Oxford University Press, New York. pp. 1277–1289.
24.
KatayamaK, SatoY, IshidaK, MoriS, and MiyamuraM. (1998). The effects of intermittent exposure to hypoxia during endurance exercise training on the ventilatory responses to hypoxia and hypercapnia in humans. Eur J Appl Physiol, 78:189–194.
25.
LawleyJS, LevineBD, WilliamsMA, MalmJ, EklundA, PolanerDM, SubudhiAW, HackettPH, and RoachRC. (2016). Cerebral spinal fluid dynamics: Effect of hypoxia and implications for high-altitude illness. J Appl Physiol, 120:251–262.
26.
LiuH, ZhangY, WuH, D'AllesandroA, YegutkinGG, SongA, SunK, LiJ, ChengNY, HuangA, Edward WenY, WengTT, LuoF, NemkovT, SunH, KellemsRE, Karmouty-QuintanaH, HansenKC, ZhaoB, SubudhiAW, Jameson-Van HoutenS, JulianCG, LoveringAT, EltzschigHK, BlackburnMR, RoachRC, and XiaY. (2016). Beneficial role of erythrocyte adenosin A2B receptor-mediated AMP-activated protein kinase activation in high-altitude hypoxia. Circulation, 134:405–421.
27.
LoeppkyJA, IcenogleMV, MaesD, RiboniK, Hinghofer-SzalkayH, and RoachR. (2005). Early fluid retention and severe acute mountain sickness. J Appl Physiol, 98:591–597.
28.
LuoY, YangX, and GaoY. (2013). Strategies for the prevention of acute mountain sickness and treatment for large groups making a rapid ascent in China. Int J Cardiol, 169:97–100.
29.
MaggioriniM, BuhlerB, WalterM, and OelzO. (1990). Prevalence of acute mountain sickness in the Swiss Alps. BMJ, 301:853–855.
30.
MaggioriniM, MullerA, HofstetterD, BartschP, and OelzO. (1998). Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med, 69:1186–1192.
31.
MairerK, WilleM, BucherT, and BurtscherM. (2009). Prevalence of acute mountain sickness in the Eastern Alps. High Alt Med Biol, 10:239–245.
32.
MandolesiG, AvanciniG, BartesaghiM, BernardiE, PomidoriL, and CogoA. (2014). Long-term monitoring of oxygen saturation at altitude can be useful in predicting the subsequent development of moderate-to-severe acute mountain sickness. Wilderness Environ Med, 25:384–391.
33.
MontgomeryAB, MillsJ, and LuceJM. (1989). Incidence of acute mountain sickness at intermediate altitude. JAMA, 261:732–734.
34.
MooreLG. (1987). Altitude aggravated illness: Examples from pregnancy and prenatal life. Ann Emerg Med, 16:965–973.
35.
MuzaSR. (2018). Wearable physiological sensors and real-time algorithms for detections of acute mountain sickness. J Appl Physiol, 124:557–563.
36.
PurkayasthaSS, RayUS, AroraBS, ChhabraPC, ThakurL, BandopadhyayP, and SelvamurthyW. (1995). Acclimatization at high altitude in gradual and acute induction. J Appl Physiol, 79:487–492.
37.
RoachR, StapanekJ, and HackettP. (2002). Acute mountain sickness and high-altitude cerebral edema. In: Medical Aspects of Harsh Environments, Volume 2. PandolfKB and BurrRE, eds. Associated Press, New York. pp. 765–793.
38.
RoachRC, BartschP, OelzO, HackettPH, and Committee LLASC. (1993). The Lake Louise Acute Mountain Sickness scoring system. In: Hypoxia and Molecular Medicine. SuttonJR, HoustonCS and CoatesG, eds. Queen City Printers, Burlington. pp. 272–274.
39.
RoachRC, MaesD, SandovalD, RobergsRA, IcenogleM, Hinghofer-SzalkayH, LiumD, and LoeppkyJA. (2000). Exercise exacerbates acute mountain sickness at simulated high altitude. J Appl Physiol, 88:581–585.
40.
RodwayGW, and MuzaSR. (2011). Fighting in thin air: Operational wilderness medicine in high Asia. Wilderness Environ Med, 22:297–303.
41.
RossRT. (1985). The random nature of cerebral mountain sickness. Lancet, 1:2.
42.
SampsonJB, KobrickJL, and JohnsonRF. (1994). Measurement of subjective reactions to extreme environments: The Environmental Symptoms Questionnaire. Mil Psych, 6:215–233.
43.
SchneiderM, BernaschD, WeymannJ, HolleR, and BärtschP. (2002). Acute mountain sickness: Influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc, 34:1886–1891.
44.
SchommerK, HammerM, HotzL, MenoldE, BärtschP, and BergerMM. (2012). Exercise intensity typical of mountain climbing does not exacerbate acute mountain sickness in normobaric hypoxia. J Appl Physiol, 113:1068–1074.
45.
SinghMV, RawalSB, and TyagiAK. (1990). Body fluid status on induction, reinduction and prolonged stay at high altitude of human volunteers. Int J Biometeorol, 34:93–97.
46.
StamperDA, SternerRT, and RobinsonSM. (1980). Evaluation of an acute mountain sickness questionnaire: Effects of intermediate-altitude staging upon subjective symptomatology. Aviat Space Environ Med, 51:379–387.
47.
WestJB. (2004). The physiologic basis of high-altitude diseases. Ann Intern Med, 141:12.
48.
WindsorJS, FirthPG, GrocottMP, RodwayGW, and MontgomeryHE. (2009). Mountain mortality: A review of deaths that occur during recreational activities in the mountains. Postgrad Med J, 85:316–321.
49.
WindsorJS, and RodwayGW. (2014). Con:pulse oximetry is useful in predicting acute mountain sickness. High Alt Med Biol, 15:442–443.
